2. Academic Validation
  3. Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study

Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study

  • Clin Cancer Res. 2019 Oct 15;25(20):6044-6051. doi: 10.1158/1078-0432.CCR-19-0798.
Suzanne Shusterman 1,  Arlene Naranjo 2,  Collin Van Ryn 3,  Jaquelyn A Hank 4,  Marguerite T Parisi 5,  Barry L Shulkin 6,  Sabah Servaes 7,  Wendy B London 8,  Hiroyuki Shimada 9,  Jacek Gan 4,  Steven D Gillies 10,  John M Maris 7,  Julie R Park 5,  Paul M Sondel 4
Affiliations

Affiliations

  • 1 Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, Massachusetts. Suzanne_Shusterman@dfci.harvard.edu.
  • 2 Children's Oncology Group Statistics and Data Center, University of Florida, Gainesville, Florida.
  • 3 Coordinating Center for Biometric Research, University of Minnesota, Twin Cities, Minneapolis, Minnesota.
  • 4 Departments of Pediatrics, Human Oncology and Genetics and the University of Wisconsin, Madison, Wisconsin.
  • 5 Seattle Children's Hospital and the University of Washington, Seattle, Washington.
  • 6 St. Jude Children's Research Hospital and the University of Tennessee Health Science Center, University of Tennessee, Memphis, Tennessee.
  • 7 Children's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • 8 Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, Massachusetts.
  • 9 Children's Hospital of Los Angeles and University of Southern California, Los Angeles, California.
  • 10 Provenance Biopharmaceuticals, Carlisle, Massachusetts.
PMID: 31358541 DOI: 10.1158/1078-0432.CCR-19-0798
Abstract

Purpose: Combining anti-GD2 (disialoganglioside) mAb with GM-CSF, IL2, and isotretinoin is now FDA-approved for high-risk neuroblastoma minimal residual disease (MRD) therapy. The humanized anti-GD2 antibody conjugated to IL2 (hu14.18-IL2) has clinical activity in neuroblastoma and is more effective in neuroblastoma-bearing mice than antibody and cytokine given separately. We therefore evaluated the safety, tolerability, and antitumor activity of hu14.18-IL2 given with GM-CSF and isotretinoin in a schedule similar to standard MRD therapy.

Patients and methods: Hu14.18-IL2 was given at the recommended phase II dose of 12 mg/m2/day on days 4-6 of a 28-day cycle with GM-CSF (250 mg/m2/dose, days 1-2 and 8-14) and isotretinoin (160 mg/m2/day, days 11-25). Tolerability was determined on the basis of the number of unacceptable toxicities observed. Response was evaluated separately for patients with disease measurable by standard radiologic criteria (stratum 1), and for patients with disease evaluable only by I123-metaiodobenzylguanidine (I123-MIBG) scan and/or bone marrow histology (stratum 2).

Results: Fifty-two patients with recurrent or refractory neuroblastoma were enrolled; 51 were evaluable for toxicity and 45 were evaluable for response. Four patients had unacceptable toxicities, well below the protocol-defined rule for tolerability. Other grade 3 and 4 nonhematologic toxicities were expected and reversible. No responses were seen in stratum 1 (n = 14). In stratum 2 (n = 31), 5 objective responses were confirmed by central review (3 complete, 2 partial).

Conclusions: Hu14.18-IL2 given in combination with GM-CSF and isotretinoin is safe and tolerable. Patients with MIBG and/or bone marrow-only disease had a 16.1% response rate, confirming activity of the combination.

Figures
Products